15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $357M | $156M | 0.0% | 0.0% | — | $2.5B | $72M |
| 2024 | $285M | $127M | 0.0% | 0.0% | — | $2.4B | $60M |
| 2023 | $236M | $14M | 0.0% | 0.0% | — | $2.4B | $41M |
| 2022 | $187M | -$78M | 0.0% | 0.0% | — | $2.5B | $49M |
| 2021 | $156M | -$113M | 0.0% | 0.0% | — | $2.4B | $112M |
| 2020 | $156M | $138M | 0.0% | 0.0% | — | $2.4B | $59M |
| 2019 | $128M | $69M | 0.0% | 0.0% | — | $2.4B | $39M |
| 2018 | $70M | $279M | 0.0% | 0.0% | — | $3.2B | $50M |
| 2017 | $26M | $158M | 0.0% | 0.0% | — | $3.4B | $519M |
| 2016 | — | $70M | — | — | — | $1.2B | $26M |
| 2015 | — | $79M | — | — | — | $1.4B | $7M |
| 2014 | — | $47M | — | — | — | $1.1B | $62M |
| 2013 | — | $34M | — | — | — | $688M | $4M |
| 2012 | — | $20M | — | — | — | $570M | $17M |
| 2011 | — | $13M | — | — | — | — | $42M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $117M | $41M | 0.0% | 0.0% | — | $2.7B | $117M |
| Dec '25 | $108M | $27M | 0.0% | 0.0% | — | $2.5B | $72M |
| Sep '25 | $92M | $23M | 0.0% | 0.0% | — | $2.6B | $201M |
| Jun '25 | $79M | $66M | 0.0% | 0.0% | — | $2.5B | $95M |
| Mar '25 | $77M | $40M | 0.0% | 0.0% | — | $2.4B | $23M |
| Dec '24 | $77M | $47M | 0.0% | 0.0% | — | $2.4B | $60M |
| Sep '24 | $74M | $30M | 0.0% | 0.0% | — | $2.5B | $63M |
| Jun '24 | $68M | $24M | 0.0% | 0.0% | — | $2.4B | $36M |
| Mar '24 | $66M | $26M | 0.0% | 0.0% | — | $2.5B | $60M |
| Dec '23 | $61M | $17M | 0.0% | 0.0% | — | $2.4B | $41M |
| Sep '23 | $60M | -$15M | 0.0% | 0.0% | — | $2.3B | $33M |
| Jun '23 | $58M | $21M | 0.0% | 0.0% | — | $2.4B | $27M |
| Mar '23 | $57M | -$9M | 0.0% | 0.0% | — | $2.4B | $34M |
| Dec '22 | $53M | -$85M | 0.0% | 0.0% | — | $2.5B | $49M |
| Sep '22 | $48M | -$50M | 0.0% | 0.0% | — | $2.4B | $26M |
| Jun '22 | $44M | $17M | 0.0% | 0.0% | — | $2.5B | $67M |
| Mar '22 | $42M | $41M | 0.0% | 0.0% | — | $2.4B | $25M |
| Dec '21 | $41M | -$24M | 0.0% | 0.0% | — | $2.4B | $112M |
| Sep '21 | $40M | $10M | 0.0% | 0.0% | — | $2.7B | $546M |
| Jun '21 | $39M | -$133M | 0.0% | 0.0% | — | $2.3B | $69M |
How the market has priced SBRA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Sabra Health Care Reit, Inc.'s revenue has grown 18.0% per year, and net income grown 2.4% per year. These are computed facts, not advice.
As of FY2025, Sabra Health Care Reit, Inc. reported $2.5B of total debt against $72M of cash.
In FY2025, gross margin was —, operating margin —, and net margin 43.6%.
As of Jun '26, Sabra Health Care Reit, Inc. traded at a price-to-earnings ratio of about 31.3× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.